Streetbeat News

SDZNY

Sandoz Group AG

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

41.52

Mkt cap

18B

Volume

1.1K

High

41.94

P/E Ratio

-2093.50

52-wk high

49.81

Low

41.52

Div yield

0.01

52-wk low

27.79

Sandoz reported strong financial results for FY 2024, with net sales of USD 10.4 billion, a 9% increase in constant currencies. The growth was driven by biosimilars and operational efficiencies. The company projects mid-single digit growth for 2025.

Portfolio Pulse from

March 05, 2025 | 6:15 am

Avecho Biotechnology Limited has entered a ten-year exclusive development and licensing agreement with Sandoz Group AG to commercialize Avecho's CBD capsule for insomnia in Australia. Avecho will receive upfront, milestone, and royalty payments, while Sandoz will handle commercial sales in Australia.

Portfolio Pulse from

March 03, 2025 | 10:15 pm

Sandoz announced the retirement of Francisco Ballester, President Region International, effective March 1, 2025. Peter Stenico will succeed him and join the Sandoz Executive Committee.

Portfolio Pulse from

February 03, 2025 | 6:15 am

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) to determine which offers a better value opportunity for investors in the Medical - Drugs sector.

Portfolio Pulse from

January 22, 2025 | 6:00 pm

Sandoz, a leader in generics and biosimilars, is set to confirm its strategic roadmap at the J.P. Morgan Healthcare Conference. The company aims to become the top biosimilar provider in the US by 2025, with three launches planned. Sandoz is well-positioned in the growing USD 200 billion market, with a strong pipeline of 28 molecules.

Portfolio Pulse from

January 14, 2025 | 6:15 am

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) to determine which stock offers better value for investors in the Medical - Drugs sector.

Portfolio Pulse from

January 06, 2025 | 6:00 pm

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) to determine which offers better value for investors in the Medical - Drugs sector.

Portfolio Pulse from

December 20, 2024 | 6:00 pm

Sandoz Group AG Sponsored ADR (SDZNY) has been upgraded to a Zacks Rank #1 (Strong Buy) due to growing optimism about its earnings prospects.

Portfolio Pulse from

December 16, 2024 | 6:15 pm

Sandoz Group AG Sponsored ADR (SDZNY) is showing a hammer chart pattern, suggesting it has found support after recent losses. Combined with upward earnings estimate revisions, this indicates a potential trend reversal.

Portfolio Pulse from

December 16, 2024 | 4:15 pm

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) as potential value investments in the Medical - Drugs sector, focusing on which might be the better undervalued stock option.

Portfolio Pulse from

December 04, 2024 | 6:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.